Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-Free Survival in Patients With Adrenocortical Carcinoma at Low-Intermediate Risk of Recurrence.

Trial Profile

Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-Free Survival in Patients With Adrenocortical Carcinoma at Low-Intermediate Risk of Recurrence.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Mitotane (Primary)
  • Indications Adenocarcinoma
  • Focus Therapeutic Use
  • Acronyms ADIUVO
  • Most Recent Events

    • 04 May 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2020.
    • 04 May 2017 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2018.
    • 18 Jun 2013 New source identified and integrated (United Kingdom Clinical Research Network: 14759).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top